Autonomix Medical, Inc. has strengthened its global intellectual property position with the grant of Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The patent, issued on July 13, 2026, covers technologies for real-time nerve sensing, mapping, and physiological monitoring. This addition expands Autonomix's portfolio to 112 issued or pending patent applications worldwide, reinforcing its competitive edge in the multi-billion-dollar denervation market.

The newly issued patent expands and reinforces Autonomix's intellectual property estate related to real-time nerve sensing, mapping, physiological monitoring, and feedback-guided neuromodulation technologies. The patented systems and methods are designed to enable more precise targeting of autonomic nerves associated with a variety of chronic disease states, including hypertension, chronic heart failure, chronic renal failure, metabolic disorders, and other conditions linked to autonomic nervous system dysfunction and renal sympathetic nerve hyperactivity.

Unlike conventional denervation approaches that rely primarily on anatomical landmarks, the patented technology incorporates sensing-enabled devices capable of detecting neural and physiological responses in real time. This closed-loop approach may enable physicians to locate neural targets more accurately, assess treatment effects during therapy delivery, and evaluate procedural success through objective physiological feedback. Corresponding patents covering related inventions have previously been issued in the United States and Europe, reinforcing Autonomix's intellectual property position across major commercial markets.

Key Technologies Covered

The Canadian patent encompasses several core innovations in nerve-targeted therapy:

Brad Hauser, Chief Executive Officer of Autonomix, emphasized the strategic importance of the patent. "Securing this Canadian patent further strengthens our competitive position and expands the intellectual property foundation supporting our precision neuromodulation platform," said Hauser. "We believe the ability to identify, monitor and modulate neural targets using real-time physiological feedback may represent a transformational advancement in nerve-targeted therapy."

Autonomix is initially developing its platform for pain management, with early trials focused on pancreatic cancer. The company views the technology as a platform capable of addressing dozens of potential indications across cardiology, hypertension, and chronic pain.

Autonomix Medical has regained compliance with the minimum bid price requirement set by Nasdaq. The company received a notification from the exchange confirming that its stock has met the necessary criteria for continued listing. This development secures the company's position on the Nasdaq Capital Market.

The notification follows a period during which the company's stock price fell below the $1.00 minimum threshold. Nasdaq rules provide a grace period for companies to regain compliance, which Autonomix Medical has successfully utilized. The company's shares will continue to trade without interruption.

Compliance Details

The specific rule in question is Nasdaq Listing Rule 5450(a)(1), which mandates a minimum bid price of $1.00 per share. Failure to comply can result in delisting. The following table outlines the key compliance metrics:

Regulatory Context

Autonomix Medical initially received a deficiency notice from Nasdaq when its closing bid price fell below the required level for 30 consecutive business days. The company had a 180-day compliance period to rectify the issue. The recent notification confirms that the stock has maintained a closing bid price of at least $1.00 for 10 consecutive business days, thereby satisfying the rule's conditions.

This compliance restoration removes the immediate threat of delisting and allows the company to focus on its operational objectives. Investors can continue to trade Autonomix Medical shares on the Nasdaq Capital Market under the ticker symbol AMIX.